Minimal time to successful intercourse after sildenafil citrate: Results of a randomized, double-blind, placebo-controlled trial

Urology

Volumn 62, Issue 3, 2003, Pages 400-403

  Padma Nathan, Harin ^a   Stecher, V J ^b   Sweeney, M ^b   Orazem, J ^b   Tseng, L J ^b   DeRiesthal, H ^b  

^a The Male Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EATING; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RHINITIS; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SINUSITIS; TIME; TREATMENT OUTCOME;

EID: 0042734896     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00567-3     Document Type: Article

References (14)

1. Pfizer Inc., New York, NY: Data on file. 2002.
2. Nichols D.J., Muirhead G.J., Harness J.A. Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects absolute bioavailability, food effects and dose proportionality . Br J Clin Pharmacol. 53:2002;5S-12S.
3. Muirhead G.J., Wilner K., Colburn W., et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol. 53:2002;21S-30S.
4. Muirhead G.J., Faulkner S., Harness J.A., et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 53:2002;37S-43S.
5. Eardley I., Ellis P., Boolell M., et al. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol. 53:2002;61S-65S.
6. Boolell M., Gepi-Attee S., Gingell J.C., et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 78:1996;257-261.
7. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
8. Rosen R.C., Riley A., Wagner G., et al. The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction . Urology. 49:1997;822-830.
9. Wei L.J., Lin D.Y., Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 84:1989;1065-1073.
10. Klotz T., Sachse R., Heidrich A., et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients a RigiScan and pharmacokinetic study . World J Urol. 19:2001;32-39.
11. Kim S., Narayanan S., Song J.C. Tadalafil an oral selective phosphodiesterase 5 inhibitor for treatment of erectile dysfunction . Formulary. 37:2002;289-296.
12. Stark S., Sachse R., Liedl T., et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol. 40:2001;181-190.
13. Padma-Nathan H., Rosen R.C., Shabsigh R., et al. Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. J Urol. 165:2001;224.
14. Padma-Nathan H, Kaufman J, and Taylor T: Earliest time to onset of erections with vardenafil determined in an at-home setting. Presented at the 28th Annual Meeting of the American Society of Andrology, March 29-April 2, 2003, Phoenix, Arizona.